Please ensure Javascript is enabled for purposes of website accessibility

Biogen and Vir Biotechnology to Collaborate to Find a Treatment for the Coronavirus

By Prosper Junior Bakiny - Mar 12, 2020 at 5:27PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The two biotech companies are still discussing the terms of the deal.

COVID-19 continues to spread worldwide. The latest situation report from the World Health Organization (WHO) shows that there are now more than 125,000 confirmed cases of the disease and more than 4,600 deaths. Several biotech companies are racing to find a vaccine or a treatment for the rapidly spreading disease.

One of these companies is Vir Biotechnology (VIR -4.06%), which focuses on developing treatments for infectious diseases. Recently, Vir announced it was partnering up with Biogen (BIIB 0.26%) to develop and manufacture antibodies that could treat COVID-19. Given the gravity of the situation, the two companies decided to start working on this project while negotiating the terms of the deal. 

Woman wearing face mask talking on the phone

Image Source: Getty Images.

Vir's experience with coronaviruses comes in handy 

On Jan. 22, Vir announced it was screening its library of antibodies to identify one that could be effective against COVID-19. The company had previous experience dealing with other coronaviruses, including Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). On Feb. 12, Vir announced it identified two antibodies with the potential to be effective against SARS-CoV-2, the virus that causes COVID-19. 

The company partnered with other companies in its quest to beat the potentially deadly disease. Vir entered into an agreement with WuXi Biologics, a China-based biologics technology platform that helps companies develop and manufacture drugs. According to the terms of the deal, WuXi Biologics "will conduct cell-line development, process and formulation development, and initial manufacturing for clinical development." WuXi Biologics will hold the right to market this treatment in China if it is approved, and Vir will market it in the rest of the world.  

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biogen Inc. Stock Quote
Biogen Inc.
BIIB
$211.93 (0.26%) $0.55
Vir Biotechnology, Inc. Stock Quote
Vir Biotechnology, Inc.
VIR
$24.84 (-4.06%) $-1.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.